Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy

Next Previous
Trial Profile

Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Stroke; Thrombosis
  • Focus Adverse reactions
  • Acronyms RE-CIRCUIT
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 15 Nov 2017 Results assessing heparin dose administered on the day of ablation and regional differences, presented at the 90th Annual Scientific Sessions of the American Heart Association.
  • 15 Nov 2017 Results of subanalysis assessing regional differences in patient characteristics, ablation procedures and bleeding incidence presented at the 90th Annual Scientific Sessions of the American Heart Association
  • 10 Nov 2017 According to a Boehringer Ingelheim media release, sub-analyses data will be presented at the American Heart Association (AHA) Scientific Sessions 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top